Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
LP-300 shows strong efficacy in lung cancer while operating losses shrink 25%.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Nova Poshta increases its consolidated net profit in H1 2026 by 24.3% amid 31.8% revenue growth
Nova Poshta, a leader in express delivery in Ukraine and part of the Nova Group, increased its consolidated net profit in the first half of 2026 by 24.3% year-on-year to UAH 2.2 billion, while revenue…
Wall Street Set To Bounce Back
(RTTNews) - Initial cues from the U.S. Futures Index suggest that Wall Street might open significantly higher on Friday, while the major averages finished lower at yesterday's close.
Revised FDI Framework Clears 29 Investments Worth ₹4,895 Crore: Government
New Delhi: The government on Friday said that 29 FDI investments have been reported under the revised framework (up to August 20), involving proposed FDI of Rs 4,895.65 crore.
Global Crude Refining Has No Margin for Error, Says Rapidan’s McNally
Bob McNally, founder and president at Rapidan Energy Group, examines pressure on the global crude refining system from increased Ukrainian attacks on Russia refiners and US facilities running at near…
Singapore’s carrots for fund managers set to sharpen competition with Hong Kong
Singapore’s latest package of tax breaks and visa incentives for fund managers could enhance its appeal as a leading asset management hub, as competition with Hong Kong intensifies for global capital…
Market correction wipes N5.42trn off NGX in 20-day slump
Sentiment on the Nigerian Exchange Limited (NGX) has turned decidedly cautious as a wave of sustained profit-taking and broad market read more Market correction wipes N5.42trn off NGX in 20-day slump